Carmat SA (EPA: ALCAR)

Market Cap	50.70M
Revenue (ttm)	6.93M
Net Income (ttm)	-53.35M
Shares Out	42.39M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,186
Open	1.196
Previous Close	1.196
Day's Range	1.190 - 1.210
52-Week Range	1.178 - 9.990
Beta	1.49
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 27, 2024

About Carmat

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 182
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCAR

Financial Performance

In 2023, Carmat's revenue was 3.84 million, an increase of 704.40% compared to the previous year's 477,000. Losses were -53.87 million, 0.35% more than in 2022.